View in EDS

LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1.

Saved in:
Bibliographic Details
Title: LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1.
Authors: Kristensen, C.A.1 (AUTHOR), Metcalf, R.2 (AUTHOR), Braña, I.3 (AUTHOR), Laban, S.4 (AUTHOR), Soria Rivas, A.5 (AUTHOR), Grose, D.6 (AUTHOR), Rubio Casadevall, J.7 (AUTHOR), Cheshuk, V.8 (AUTHOR), Dieter, S.M.9 (AUTHOR), Lopez Pousa, A.10 (AUTHOR), Kasper-Virchow, S.11 (AUTHOR), Doger de Spéville, B.12 (AUTHOR), Covela, M.13 (AUTHOR), Vogl, F.D.14 (AUTHOR), Mueller, C.15 (AUTHOR), Triebel, F.16 (AUTHOR)
Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1227-S1227. 1p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 179693604
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Kristensen%2C+C%2EA%2E%22">Kristensen, C.A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Metcalf%2C+R%2E%22">Metcalf, R.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Braña%2C+I%2E%22">Braña, I.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Laban%2C+S%2E%22">Laban, S.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Soria+Rivas%2C+A%2E%22">Soria Rivas, A.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Grose%2C+D%2E%22">Grose, D.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rubio+Casadevall%2C+J%2E%22">Rubio Casadevall, J.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cheshuk%2C+V%2E%22">Cheshuk, V.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dieter%2C+S%2EM%2E%22">Dieter, S.M.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lopez+Pousa%2C+A%2E%22">Lopez Pousa, A.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kasper-Virchow%2C+S%2E%22">Kasper-Virchow, S.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Doger+de+Spéville%2C+B%2E%22">Doger de Spéville, B.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Covela%2C+M%2E%22">Covela, M.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vogl%2C+F%2ED%2E%22">Vogl, F.D.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mueller%2C+C%2E%22">Mueller, C.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Triebel%2C+F%2E%22">Triebel, F.</searchLink><relatesTo>16</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2024 Supplement 2, Vol. 35, pS1227-S1227. 1p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=179693604
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2024.08.2274
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: S1227
    Titles:
      – TitleFull: LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kristensen, C.A.
      – PersonEntity:
          Name:
            NameFull: Metcalf, R.
      – PersonEntity:
          Name:
            NameFull: Braña, I.
      – PersonEntity:
          Name:
            NameFull: Laban, S.
      – PersonEntity:
          Name:
            NameFull: Soria Rivas, A.
      – PersonEntity:
          Name:
            NameFull: Grose, D.
      – PersonEntity:
          Name:
            NameFull: Rubio Casadevall, J.
      – PersonEntity:
          Name:
            NameFull: Cheshuk, V.
      – PersonEntity:
          Name:
            NameFull: Dieter, S.M.
      – PersonEntity:
          Name:
            NameFull: Lopez Pousa, A.
      – PersonEntity:
          Name:
            NameFull: Kasper-Virchow, S.
      – PersonEntity:
          Name:
            NameFull: Doger de Spéville, B.
      – PersonEntity:
          Name:
            NameFull: Covela, M.
      – PersonEntity:
          Name:
            NameFull: Vogl, F.D.
      – PersonEntity:
          Name:
            NameFull: Mueller, C.
      – PersonEntity:
          Name:
            NameFull: Triebel, F.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 09
              Text: 2024 Supplement 2
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 09237534
          Numbering:
            – Type: volume
              Value: 35
          Titles:
            – TitleFull: Annals of Oncology
              Type: main
ResultId 1